N-(4-Hydroxyphenyl)retinamide induced differentiation with repression of telomerase and cell cycle to increase interferon-γ sensitivity for apoptosis in human glioblastoma cells

Cancer Letters

Volumn 261, Issue 1, 2008, Pages 26-36

  Janardhanan, Rajiv ^a   Banik, Naren L ^a   Ray, Swapan K ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

4 HPR; Apoptosis; Differentiation; Glioblastoma; IFN

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; CYCLIN DEPENDENT KINASE 2; CYTOCHROME C; FENRETINIDE; GAMMA INTERFERON; PROTEIN BAX; PROTEIN BCL 2; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASTROCYTE; ASTROCYTOMA; BRAIN TUMOR; CANCER INHIBITION; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOSOL; ENZYME ACTIVATION; ENZYME REPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; MITOCHONDRION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; WESTERN BLOTTING;

APOPTOSIS; CASPASES; CELL CYCLE; CELL DIFFERENTIATION; FENRETINIDE; GLIOBLASTOMA; HUMANS; INTERFERON TYPE II; MODELS, BIOLOGICAL; TELOMERASE; TUMOR CELLS, CULTURED;

EID: 38949215068     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.11.016     Document Type: Article

References (46)

1. Ray S.K., Patel S.J., Welsh C.T., Wilford G.G., Hogan E.L., and Banik N.L. Molecular evidence of apoptotic death in malignant brain tumors including glioblastoma multiforme: upregulation of calpain and caspase-3. J. Neurosci. Res. 69 (2002) 197-206
2. Kleihues P., Louis D.N., Scheithauer B.W., Rorke L.B., Reifenberger G., Burger P.C., et al. The WHO classification of tumors of the nervous system. J. Neuropathol. Exp. Neurol. 61 (2002) 215-225
3. Parney I.F., and Chang S.M. Current chemotherapy for glioblastoma. Cancer J. 9 (2003) 149-156
4. Parney I.F., Hao C., and Petruk K.C. Glioblastoma immunology and immunotherapy. Neurosurgery 46 (2000) 778-791
5. Chambon P.A. Decade of molecular biology of retinoic acid receptors. FASEB J. 10 (1996) 940-954
6. Altucci L., and Gronemeyer H. The promise of retinoids to fight against cancer. Nat. Rev. Cancer 1 (2001) 181-193
7. Soprano D.R., Qin P., and Soprano K.J. Retinoic acid receptors and cancers. Annu. Rev. Nutr. 24 (2004) 201-221
8. Wu S., Zhang Z.P., Zhang D., Soprano D.R., and Soprano K.J. Reduction of both RAR and RXR levels is required to maximally alter sensitivity of CA-OV3 ovarian tumor cells to growth suppression by all-trans retinoic acid. Exp. Cell Res. 237 (1997) 118-126
9. Bhatnagar R., Abou-Issa H., Curley Jr. R.W., Koolemans-Beynen A., Moeschberger M.L., and Webb T.E. Growth suppression of human breast carcinoma cells in culture by N-(4-hydroxyphenyl)retinamide and its glucuronide and through synergism with glucarate. Biochem. Pharmacol. 41 (1991) 1471-1477
10. Kalemkerian G.P., Slusher R., Ramalingam S., Gadgeel S., and Mabry M. Growth inhibition and induction of apoptosis by fenretinide in small-cell lung cancer cell lines. J. Natl. Cancer Inst. 87 (1995) 1674-1680
11. Sabichi A.L., Hendricks D.T., Bober M.A., and Birrer M.J. Retinoic acid receptor β expression and growth inhibition of gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl)retinamide. J. Natl. Cancer Inst. 90 (1998) 597-605
12. Panigone S., Debernardi S., Taya Y., Fontanella E., Airoldi R., and Delia D. pRb and Cdk regulation by N-(4-hydroxyphenyl)retinamide. Oncogene 19 (2000) 4035-4041
13. Haque A., Das A., Hajiaghamohseni L.M., Younger A., Banik N.L., and Ray S.K. Induction of apoptosis and immune response by all-trans retinoic acid plus interferon-gamma in human malignant glioblastoma T98G and U87MG cells. Cancer Immunol. Immunother. 56 (2007) 615-625
14. Burke F., East N., Upton C., Patel K., and Balkwill F.R. Interferon gamma induces cell cycle arrest and apoptosis in a model of ovarian cancer: enhancement of effect by batimastat. Eur. J. Cancer 33 (1997) 1114-1121
15. Cory S., and Adams J.M. The Bcl2 family: regulators of the cellular life-or-death switch. Nat. Rev. Cancer 2 (2002) 647-656
16. Shi Y. Mechanisms of caspase activation and inhibition during apoptosis. Mol. Cell 9 (2002) 459-470
17. Altieri D.C. Validating survivin as a cancer therapeutic target. Nat. Rev. Cancer 3 (2003) 46-54
18. Conway E.M., Pollefeyt S., Steiner-Mosonyi M., Luo W., Devriese A., Lupu F., et al. Deficiency of survivin in transgenic mice exacerbates Fas-induced apoptosis via mitochondrial pathways. Gastroenterology 123 (2002) 619-631
19. Grossman D., Kim P.J., Blanc-Brude O.P., Brash D.E., Tognin S., Marchisio P.C., et al. Transgenic expression of survivin in keratinocytes counteracts UVB-induced apoptosis and cooperates with loss of p53. J. Clin. Invest. 108 (2001) 991-999
20. Karmakar S., Weinberg M.S., Banik N.L., Patel S.J., and Ray S.K. Activation of multiple molecular mechanisms for apoptosis in human malignant glioblastoma T98G and U87MG cells treated with sulforaphane. Neuroscience 141 (2006) 1265-1280
21. Ray S.K., Karmakar S., Nowak M.W., and Banik N.L. Inhibition of calpain and caspase-3 prevented apoptosis and preserved electrophysiological properties of voltage-gated and ligand-gated ion channels in rat primary cortical neurons exposed to glutamate. Neuroscience 139 (2006) 577-595
22. Luo X., Budihardjo I., Zou H., Slaughter C., and Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94 (1998) 481-490
23. Murphy K.M., Streips U.N., and Lock R.B. Bax membrane insertion during Fas (CD95)-induced apoptosis precedes cytochrome c release and is inhibited by Bcl-2. Oncogene 18 (1999) 5991-5999
24. Cain K., Brown D.G., Langlais C., and Cohen G.M. Caspase activation involves the formation of the aposome, a large (approximately 700 kDa) caspase-activating complex. J. Biol. Chem. 274 (1999) 22686-22692
25. Saleh A., Srinivasula S.M., Acharya S., Fishel R., and Alnemri E.S. Cytochrome c and dATP-mediated oligomerization of Apaf-1 is a prerequisite for procaspase-9 activation. J. Biol. Chem. 274 (1999) 17941-17945
26. Hayashi Y., Ueki K., Waha A., Wiestler O.D., Louis D.N., and von Deimling A. Association of EGFR gene amplification and CDKN2 (p16/MTS1) gene deletion in glioblastoma multiforme. Brain Pathol. 7 (1997) 871-875
27. Hegi M.E., zur Hausen A., Ruedi D., Malin G., and Kleihues P. Hemizygous or homozygous deletion of the chromosomal region containing the p16INK4a gene is associated with amplification of the EGF receptor gene in glioblastomas. Int. J. Cancer 73 (1997) 57-63
28. Dai C., and Holland E.C. Astrocyte differentiation states and glioblastoma formation. Cancer J. 9 (2003) 72-81
29. Dowlatshahi K., Mehta R.G., Thomas C.F., Dinger N.M., and Moon R.C. Therapeutic effect of N-(4-hydroxyphenyl)retinamide on N-methyl-N-nitrosourea-induced rat mammary cancer. Cancer Lett. 47 (1989) 187-192
30. Igawa M., Tanabe T., Chodak G.W., and Rukstalis D.B. N-(4-Hydroxyphenyl)retinamide induces cell cycle specific growth inhibition in PC3 cells. Prostate 24 (1994) 299-305
31. Pienta K.J. The epidemiology of prostate cancer: clues for chemoprevention. In Vivo 8 (1994) 419-422
32. Veronesi U., Mariani L., Decensi A., Formelli F., Camerini T., Miceli R., et al. Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann. Oncol. 17 (2006) 1065-1071
33. Naik H.R., Kalemkerian G., and Pienta K.J. 4-Hydroxyphenylretinamide in the chemoprevention of cancer. Adv. Pharmacol. 33 (1995) 315-347
34. Galderisi U., Jori F.P., and Giordano A. Cell cycle regulation and neural differentiation. Oncogene 22 (2003) 5208-5219
35. Macaluso M., Montanari M., and Giordano A. Rb family proteins as modulators of gene expression and new aspects regarding the interaction with chromatin remodeling enzymes. Oncogene 25 (2006) 5263-5267
36. Chakravarti A., Zhai G.G., Zhang M., Malhotra R., Latham D.E., Delaney M.A., et al. Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms. Oncogene 23 (2004) 7494-7506
37. Katoh M., Wilmotte R., Belkouch M.C., de Tribolet N., Pizzolato G., and Dietrich P.Y. Survivin in brain tumors: an attractive target for immunotherapy. J. Neurooncol. 64 (2003) 71-76
38. Ambrosini G., Adida C., and Altieri D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med. 3 (1997) 917-921
39. Kobayashi K., Hatano M., Otaki M., Ogasawara T., and Tokuhisa T. Expression of a murine homologue of the inhibitor of apoptosis protein is related to cell proliferation. Proc. Natl. Acad. Sci. USA 96 (1999) 1457-1462
40. Vader G., Medema R.H., and Lens S.M. The chromosomal passenger complex: guiding Aurora-B through mitosis. J. Cell Biol. 173 (2006) 833-837
41. Lens S.M., and Medema R.H. The survivin/Aurora B complex: its role in coordinating tension and attachment. Cell Cycle 2 (2003) 507-510
42. Park H.R., Min S.K., Cho H.D., Kim K.H., Shin H.S., and Park Y.E. Expression profiles of p63, p53, survivin, and hTERT in skin tumors. J. Cutan. Pathol. 31 (2004) 544-549
43. Wurl P., Kappler M., Meye A., Bartel F., Kohler T., Lautenschlager C., et al. Co-expression of survivin and TERT and risk of tumour-related death in patients with soft-tissue sarcoma. Lancet 359 (2002) 943-945
44. Vogel C., Hager C., and Bastians H. Mechanisms of mitotic cell death induced by chemotherapy-mediated G2 checkpoint abrogation. Cancer Res. 67 (2007) 339-345
45. Zou H., Yang R., Hao J., Wang J., Sun C., Fesik S.W., et al. Regulation of the Apaf-1/caspase-9 apoptosome by caspase-3 and XIAP. J. Biol. Chem. 278 (2003) 8091-8098
46. Srinivasula S.M., Ahmad M., Fernandes-Alnemri T., and Alnemri E.S. Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization. Mol. Cell 1 (1998) 949-957